Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| GSK plc American Depositary Shares (Each representing two) | Ensovibep (VIR-7831 / GSK4182136) - (ACTIV-3) | Mild to moderate COVID-19 | Phase 3 | Withdrawn | Intravenous | COVID-19 |
| GSK plc American Depositary Shares (Each representing two) | Bintrafusp alfa | Non-small Cell Lung Cancer | Phase 3 | Intravenous | Oncology | |
| GSK plc American Depositary Shares (Each representing two) | BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8) | Multiple Myeloma | BLA Filing | Data Released | BLENREP intravenous POMALYST oral Dexamethasone oral | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Jemperli (dostarlimab) - (AZUR-1) | dMMR/MSI-H rectal cancer | Phase 3 | Ongoing | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Belrestotug (EOS-448/GSK4428859A) - (GALAXIES Lung-201) | 1L non-small cell lung cancer (NSCLC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | VAT0002 (booster) | COVID-19 vaccine | Phase 3 | Ongoing | Intramuscular | COVID-19 |
| GSK plc American Depositary Shares (Each representing two) | Bepirovirsen | Hepatitis B virus | Phase 3 | Subcutaneous | Antiviral | |
| GSK plc American Depositary Shares (Each representing two) | Latozinemab (AL001) - (INFRONT-3) | Frontotemporal Dementia | Phase 3 | Trial Discontinued | intravenous | Neurology |
